# OnCo record nct06456138 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06456138/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06456138", "NCT06456138" ;
  schema:name "Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC"@en ;
  schema:description "A phase 1/2 trial of trametinib, anlotinib and tislelizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06456138/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06456138> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/anlotinib/>, <https://onco.cc/drugs/tislelizumab/> ;
  onco:companies <https://onco.cc/companies/beone/>, <https://onco.cc/companies/sino-biopharm/>, <https://onco.cc/companies/novartis/> .